Overview Dividends

(ZBH) Zimmer Biomet Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98956P1021

Knee, Hip, Sports Medicine, Trauma, Craniomaxillofacial

ZBH EPS (Earnings per Share)

EPS Growth (3Y CAGR): 10.32%
EPS Trend (3Y Correlation): 48.4%

ZBH Revenue

Revenue Growth (3Y CAGR): 8.26%
Revenue Trend (3Y Correlation): 77.5%

Description: ZBH Zimmer Biomet Holdings October 16, 2025

Zimmer Bioper (NYSE: ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and reconstructive solutions-including knee and hip implants, sports-medicine devices, trauma and extremities products, and craniomaxillofacial/ thoracic fixation systems. Its offerings span hardware, bone-cement and data-driven surgical platforms that serve orthopedic surgeons, neurosurgeons, hospitals and specialty distributors worldwide.

In fiscal 2023 the company reported roughly $7.6 billion in revenue, with a 13 % operating margin-both modestly above the industry median of ~11 % for large orthopedic OEMs. Growth is being driven by three measurable levers: (1) an aging U.S. and European population that raises demand for joint replacement (U.S. joint-replacement procedures are projected to rise ~2 % annually through 2030); (2) expanding sales in emerging markets where per-capita orthopedic spend is still low but growing at ~8 % CAGR; and (3) incremental revenue from data-analytics services tied to its digital surgery platform, which now contributes ~3 % of total sales. A material risk is ongoing Medicare reimbursement pressure, which could compress margins if policy changes reduce payment rates for joint-replacement procedures.

For a deeper, data-driven assessment of ZBH’s valuation dynamics-including forward-looking cash-flow models and peer-adjusted multiples-explore the detailed analyst toolkit on ValueRay.

ZBH Stock Overview

Market Cap in USD	19,921m
Sub-Industry	Health Care Equipment
IPO / Inception	2001-07-25

ZBH Stock Ratings

Growth Rating	-37.6%
Fundamental	65.5%
Dividend Rating	43.6%
Return 12m vs S&P 500	-23.4%
Analyst Rating	3.45 of 5

ZBH Dividends

Dividend Yield 12m	0.96%
Yield on Cost 5y	0.74%
Annual Growth 5y	0.74%
Payout Consistency	97.1%
Payout Ratio	15.5%

ZBH Growth Ratios

Growth Correlation 3m	-31.7%
Growth Correlation 12m	-56.2%
Growth Correlation 5y	-74.7%
CAGR 5y	-1.62%
CAGR/Max DD 3y (Calmar Ratio)	-0.04
CAGR/Mean DD 3y (Pain Ratio)	-0.09
Sharpe Ratio 12m	0.55
Alpha	-22.42
Beta	0.667
Volatility	22.37%
Current Volume	1473.8k
Average Volume 20d	1126.6k
Stop Loss	96.8 (-3.1%)
Signal	1.03

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (823.4m TTM) > 0 and > 6% of Revenue (6% = 470.0m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 1.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 30.05% (prev 13.70%; Δ 16.35pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.66b > Net Income 823.4m (YES >=105%, WARN >=100%)

Net Debt (7.02b) to EBITDA (2.28b) ratio: 3.08 <= 3.0 (WARN <= 3.5)

Current Ratio 1.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (198.3m) change vs 12m ago -3.92% (target <= -2.0% for YES)

Gross Margin 71.06% (prev 71.78%; Δ -0.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 35.30% (prev 34.97%; Δ 0.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.72 (EBITDA TTM 2.28b / Interest Expense TTM 261.7m) >= 6 (WARN >= 3)

Altman Z'' 3.79

(A) 0.10 = (Total Current Assets 5.05b - Total Current Liabilities 2.70b) / Total Assets 22.87b

(B) 0.50 = Retained Earnings (Balance) 11.34b / Total Assets 22.87b

(D) 1.07 = Book Value of Equity 11.05b / Total Liabilities 10.33b

Total Rating: 3.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.45

1. Piotroski 6.50pt = 1.50

2. FCF Yield 5.29% = 2.64

3. FCF Margin 18.18% = 4.54

4. Debt/Equity 0.60 = 2.32

5. Debt/Ebitda 3.08 = -1.88

6. ROIC - WACC (= -1.97)% = -2.46

7. RoE 6.62% = 0.55

8. Rev. Trend 77.52% = 5.81

9. EPS Trend 48.38% = 2.42

What is the price of ZBH shares?

As of November 04, 2025, the stock is trading at USD 99.88 with a total of 1,473,839 shares traded.
Over the past week, the price has changed by -3.14%, over one month by -0.89%, over three months by +8.36% and over the past year by -7.00%.

Is Zimmer Biomet Holdings a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Zimmer Biomet Holdings (NYSE:ZBH) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 65.45 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZBH is around 90.64 USD . This means that ZBH is currently overvalued and has a potential downside of -9.25%.

Is ZBH a buy, sell or hold?

Zimmer Biomet Holdings has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold ZBH.

Strong Buy: 5
Buy: 6
Hold: 16
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the ZBH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	110.7	10.8%
Analysts Target Price	110.7	10.8%
ValueRay Target Price	99.1	-0.8%

ZBH Fundamental Data Overview November 02, 2025

Market Cap USD = 19.92b (19.92b USD * 1.0 USD.USD)
P/E Trailing = 24.5268
P/E Forward = 11.6009
P/S = 2.5429
P/B = 1.5685
P/EG = 1.0264
Beta = 0.667
Revenue TTM = 7.83b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 2.28b USD
Long Term Debt = 6.75b USD (from longTermDebt, last quarter)
Short Term Debt = 820.0m USD (from shortTermDebt, last quarter)
Debt = 7.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.02b USD (from netDebt column, last quarter)
Enterprise Value = 26.94b USD (19.92b + Debt 7.57b - CCE 556.9m)
Interest Coverage Ratio = 4.72 (Ebit TTM 1.23b / Interest Expense TTM 261.7m)
FCF Yield = 5.29% (FCF TTM 1.42b / Enterprise Value 26.94b)
FCF Margin = 18.18% (FCF TTM 1.42b / Revenue TTM 7.83b)
Net Margin = 10.51% (Net Income TTM 823.4m / Revenue TTM 7.83b)
Gross Margin = 71.06% ((Revenue TTM 7.83b - Cost of Revenue TTM 2.27b) / Revenue TTM)
Gross Margin QoQ = 71.49% (prev 71.20%)
Tobins Q-Ratio = 1.18 (Enterprise Value 26.94b / Total Assets 22.87b)
Interest Expense / Debt = 1.05% (Interest Expense 79.3m / Debt 7.57b)
Taxrate = 31.70% (71.2m / 224.6m)
NOPAT = 843.2m (EBIT 1.23b * (1 - 31.70%))
Current Ratio = 1.87 (Total Current Assets 5.05b / Total Current Liabilities 2.70b)
Debt / Equity = 0.60 (Debt 7.57b / totalStockholderEquity, last quarter 12.53b)
Debt / EBITDA = 3.08 (Net Debt 7.02b / EBITDA 2.28b)
Debt / FCF = 4.93 (Net Debt 7.02b / FCF TTM 1.42b)
Total Stockholder Equity = 12.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 823.4m / Total Assets 22.87b)
RoE = 6.62% (Net Income TTM 823.4m / Total Stockholder Equity 12.44b)
RoCE = 6.43% (EBIT 1.23b / Capital Employed (Equity 12.44b + L.T.Debt 6.75b))
RoIC = 4.36% (NOPAT 843.2m / Invested Capital 19.32b)
WACC = 6.33% (E(19.92b)/V(27.49b) * Re(8.47%) + D(7.57b)/V(27.49b) * Rd(1.05%) * (1-Tc(0.32)))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.50%
[DCF Debug] Terminal Value 75.98% ; FCFE base≈1.30b ; Y1≈1.24b ; Y5≈1.19b
Fair Price DCF = 99.51 (DCF Value 19.71b / Shares Outstanding 198.1m; 5y FCF grow -6.20% → 3.0% )
EPS Correlation: 48.38 | EPS CAGR: 10.32% | SUE: 3.79 | # QB: 1
Revenue Correlation: 77.52 | Revenue CAGR: 8.26% | SUE: 1.50 | # QB: 1

Additional Sources for ZBH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle